DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing

DAFNA Capital Management LLC sold 34,405 shares of iShares Biotechnology ETF (IBB) Quarter-end position value decreased by $3.31 million, reflecting both trading and stock price effects Trade represented a 1.3% reduction of 13F reportable assets under management Post-trade holding: 68,095 shares valued at $11.49 million IBB accounted for 2.67% of fund AUM after the trade, placing it outside the fund's top five holdings